Company: BIAF
Filing Date: 2025-09-25
Form Type: S-1/A
Source: 0001493152-25-014878
Chunk: 9

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-09-25
Form: S-1/A
Chunk 9
---
.52 per share, which warrants are not exercisable until our stockholder approve such exercise.

On September 2, 2025, we entered into
agreements with the holders of our August 2025 Warrants and the warrants issued in our May 2025 public offering (the “May 2025
Warrants”) pursuant to which the Floor Price (as such term is defined in each of the August 2025 Warrants and the May 2025 Warrants)
was increased, effective as of August 12, 2025, from $3.00 to $4.50 per share.

On September 17, 2025, we filed with
the Secretary of State of the State of Delaware a certificate of amendment to our certificate of incorporation to effect a one-for-thirty
(1-for-30) reverse split of our issued and outstanding shares of Common Stock. The Reverse Stock Split became effective as of 4:01 p.m.
Eastern Time on September 18, 2025, and our Common Stock began trading on a split-adjusted basis when Nasdaq opened on September 19,
2025. All share and per share information in this prospectus (other than in the historical financial statements incorporated herein by
reference) has been adjusted to reflect the reverse stock split.

Corporate Information

We were incorporated in the State of Delaware on March 26, 2014. Our principal executive office is located at 3300 Nacogdoches Road, Suite 216, San Antonio, Texas 78217, and our telephone number at that address is (210) 698-5334. Our website address is https://www.bioaffinitytech.com/. Information contained on or that can be accessed through our website is not incorporated by reference into this prospectus. Investors should not consider any such information to be part of this prospectus.

Implications of Being an Emerging Growth Company and a Smaller Reporting Company

We qualify as an “emerging growth company” (an “EGC”) as defined in the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”). As an EGC, for up to five years, we may elect to take advantage of certain specified exemptions from reporting and other regulatory requirements that are otherwise generally applicable to public companies. For example, these exemptions would allow us to:

| ● | present                                                                                                                    
 two, rather than three, years of audited financial statements with correspondingly reduced disclosure in the “Management’s 
 Discussion